Each year, the American Society of Clinical Oncology gathers the cancer therapy developers during five days to present their latest results. Roche seems to be the European winner of this roundup, with amazing results of alectinib in non-small cell lung cancer (NSCLC).
Roche’s investigational medicine alectinib shrank tumors in nearly half of patients suffering from this specific type of lung cancer. Even more impressive, alectinib showed response rates of up to 69% in the central nervous system in people for whom the cancer had spread to the brain.
Alectinib, which has been granted Breakthrough Therapy Designation, is an investigational oral medicine created at Chugai Kamakura Research Laboratories (a company with belongs to Roche) and is being developed for people with NSCLC whose tumours are identified as ALK+.
Roche also announced, via its american subsidiary Genentech, results from a Phase II study in people with previously treated non-small cell lung cancer. The study showed that MPDL3280A doubled the likelihood of survival in people whose cancer expressed the highest levels of PD-L1 (programmed death ligand-1) compared to standard chemotherapy.